Get Started
Companies › KYMR

Kymera Therapeutics

KYMR · NASDAQ
Mid ClinicalMixed

Kymera is pioneering targeted protein degradation (TPD) to develop oral small molecule drugs that can achieve biologics-like efficacy. The company focuses on historically undruggable targets (transcription factors, scaffolding kinases) in immunology and inflammation, with a pipeline of first-in-class degraders targeting STAT6, IRF5, and IRAK4.

Market Cap
$6.0B
Cash Runway
Into 2029 (per presentation)
Pipeline
3 Assets
Priority
High
Investment Thesis

Bull Case

  • KT-621 Phase 1b data matches Dupixent - oral could transform $20B+ market
  • KT-579 preclinical is best-in-class - 100% survival vs 67% vehicle in lupus
  • Platform validated across STAT6, IRF5, IRAK4 - multiple shots on goal
  • Strategic partnerships (Sanofi, Gilead) validate platform and provide funding
  • Oral convenience could expand market penetration from 1-3% to 10%+

Bear Case

  • KT-621 Phase 1b was open-label - need placebo-controlled data to confirm
  • First-in-class transcription factor degraders - unknown unknowns
  • KT-474 QTc issue raises questions (though KT-485 designed to address)
  • Long development timelines - Phase 2b data not until 2027
  • Competitive pressure from Dupixent ($13B franchise) and JAK inhibitors

Pipeline

Asset Target Stage Lead Indication Next Catalyst
KT-485 IRAK4 Phase 1 Hidradenitis Suppurativa (HS) KT-485 Phase 1 initiation (2026)
KT-579 IRF5 Phase 1 Systemic Lupus Erythematosus (SLE) Phase 1 HV trial initiation (Q1 2026)
KT-621 STAT6 Phase 2b Atopic Dermatitis BROADEN2 Phase 2b AD enrollment completion (2026)
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy